SCHEMBL7899005

SCHEMBL7899005

Oc1ccc(N2CCC(NCCCc3ccccc3)CC2)cc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ME3 Q16798 2/20 0.60
GRIN2B Q13224 9/20 0.58
SIGMAR1 Q99720 3/20 0.55
GRIN1 Q05586 1/20 0.55
NPC1 O15118 1/20 0.52
ALDH1A1 P00352 1/20 0.52
GAA P10253 1/20 0.52
MAPT P10636 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
DRD4 P21917 2/20 0.51
SLC6A2 P23975 1/20 0.50
SLC6A4 P31645 1/20 0.50
SLC6A3 Q01959 1/20 0.50
ACHE P22303 1/20 0.49
BACE1 P56817 1/20 0.49
ME2 P23368 1/20 0.49
ME1 P48163 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7900897 0.96 GRIN2B (0.59) ME3GRIN2BSIGMAR1GRIN1NPC1
SCHEMBL7897978 0.92 ME3 (0.62) ME3GRIN2BSIGMAR1NPC1ALDH1A1
SCHEMBL7899612 0.84 GRIN2B (0.61) GRIN2BSIGMAR1GRIN1GAAMAPT
SCHEMBL7898015 0.82 KDM4E (0.54) GRIN2BSIGMAR1GRIN1SMN1; SMN2SLC6A2
SCHEMBL7844261 0.82 VCP (0.60) ME3GRIN2BSIGMAR1GRIN1MAPT
SCHEMBL7891487 0.81 MCHR1 (0.47) ME3GRIN2BNPC1ALDH1A1GAA
SCHEMBL7898024 0.80 ME3 (0.44) ME3GRIN2BSIGMAR1NPC1ALDH1A1
SCHEMBL5689944 0.78 GRIN2B (0.61) GRIN2BSIGMAR1GRIN1
SCHEMBL5689946 0.78 GRIN2B (0.61) GRIN2BSIGMAR1GRIN1
SCHEMBL5690203 0.78 GRIN2B (0.61) GRIN2BSIGMAR1GRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6184236-B1 Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative HOFFMANN-LA ROCHE INC. 2001-02-06 US claimed
EP-0982026-A2 Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers F. HOFFMANN-LA ROCHE AG (CH) 2000-03-01 EP claimed
US-6184236-B1 Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative HOFFMANN-LA ROCHE INC. 2001-02-06 US disclosed
EP-0982026-A2 Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers F. HOFFMANN-LA ROCHE AG (CH) 2000-03-01 EP disclosed